NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 180 filers reported holding NEKTAR THERAPEUTICS in Q2 2016. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,651,000 | -25.8% | 515,907 | -11.9% | 0.01% | -12.5% |
| Q2 2022 | $2,225,000 | +73.4% | 585,493 | +146.0% | 0.01% | +100.0% |
| Q1 2022 | $1,283,000 | -60.1% | 238,019 | 0.0% | 0.00% | -55.6% |
| Q4 2021 | $3,216,000 | -11.1% | 238,019 | +18.2% | 0.01% | -18.2% |
| Q3 2021 | $3,618,000 | +53.8% | 201,441 | +46.9% | 0.01% | +37.5% |
| Q2 2021 | $2,353,000 | +1.1% | 137,138 | +17.8% | 0.01% | 0.0% |
| Q1 2021 | $2,328,000 | +8.0% | 116,424 | -8.2% | 0.01% | 0.0% |
| Q4 2020 | $2,155,000 | +3.4% | 126,778 | +0.9% | 0.01% | 0.0% |
| Q3 2020 | $2,084,000 | -25.6% | 125,599 | +3.9% | 0.01% | -33.3% |
| Q2 2020 | $2,800,000 | +23.2% | 120,913 | -5.0% | 0.01% | +9.1% |
| Q1 2020 | $2,272,000 | -17.3% | 127,277 | 0.0% | 0.01% | +10.0% |
| Q4 2019 | $2,747,000 | +13.1% | 127,277 | -4.5% | 0.01% | +11.1% |
| Q3 2019 | $2,428,000 | -87.4% | 133,300 | -75.3% | 0.01% | -87.3% |
| Q2 2019 | $19,213,000 | +5.9% | 540,000 | 0.0% | 0.07% | +4.4% |
| Q1 2019 | $18,144,000 | +5.1% | 540,000 | +2.9% | 0.07% | -8.1% |
| Q4 2018 | $17,256,000 | +169.6% | 525,000 | +400.0% | 0.07% | +208.3% |
| Q3 2018 | $6,401,000 | +24.8% | 105,000 | 0.0% | 0.02% | +26.3% |
| Q2 2018 | $5,127,000 | -54.0% | 105,000 | 0.0% | 0.02% | -55.8% |
| Q1 2018 | $11,157,000 | +77.9% | 105,000 | 0.0% | 0.04% | +79.2% |
| Q4 2017 | $6,271,000 | +148.8% | 105,000 | 0.0% | 0.02% | +140.0% |
| Q3 2017 | $2,520,000 | +22.7% | 105,000 | 0.0% | 0.01% | +25.0% |
| Q2 2017 | $2,053,000 | -16.7% | 105,000 | 0.0% | 0.01% | -20.0% |
| Q1 2017 | $2,464,000 | +91.3% | 105,000 | 0.0% | 0.01% | +66.7% |
| Q4 2016 | $1,288,000 | -28.6% | 105,000 | 0.0% | 0.01% | -25.0% |
| Q3 2016 | $1,804,000 | +20.7% | 105,000 | 0.0% | 0.01% | +14.3% |
| Q2 2016 | $1,494,000 | +3.5% | 105,000 | 0.0% | 0.01% | 0.0% |
| Q1 2016 | $1,444,000 | -59.2% | 105,000 | -50.0% | 0.01% | 0.0% |
| Q4 2015 | $3,538,000 | +207.4% | 210,000 | +100.0% | 0.01% | +40.0% |
| Q3 2015 | $1,151,000 | -12.4% | 105,000 | 0.0% | 0.01% | 0.0% |
| Q2 2015 | $1,314,000 | +13.8% | 105,000 | 0.0% | 0.01% | 0.0% |
| Q1 2015 | $1,155,000 | -29.1% | 105,000 | 0.0% | 0.01% | -16.7% |
| Q4 2014 | $1,628,000 | +28.5% | 105,000 | 0.0% | 0.01% | +20.0% |
| Q3 2014 | $1,267,000 | -5.9% | 105,000 | 0.0% | 0.01% | 0.0% |
| Q2 2014 | $1,346,000 | – | 105,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |